Abstract: A process for controlling the regeneration of boron trifluoride catalyst complexes in the production of carboxylic acids and other products using boron trifluoride hydrates as a catalyst. Catalyst strength is determined by measuring the electrical conductivity of the catalyst recovered from hydrolysis. If the conductivity is greater than a predetermined value, the hydrolysis water rate is reduced and if the conductivity is leas than a predetermined value, the hydrolysis water rate is increased. Conductivity is determined by a toroidal conductivity sensor and a control valve responsive to operation of the conductivity sensor serves to increase or decrease the flow rate accordingly.
Abstract: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT).
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
January 13, 1998
Assignees:
University of Maryland, Pharmacia & Upjohn S.p.A.
Inventors:
Robert Schwarcz, Mario Varasi, Arturo Della Torre, Carmela Speciale, Alberto Bianchetti
Abstract: An antimicrobial composition for application to exposed wounds such as burns and ulcers includes a quaternary ammonium compound blend, a stabilizer, a nonylphenol polyethylene glycol ether, a hydrophilic polymer, sodium lithium magnesium silicate, a hydrophobic waterproofing agent, aluminum sulfate, triethanolamine and water.
Type:
Grant
Filed:
July 26, 1995
Date of Patent:
December 16, 1997
Assignee:
International Laboratory Technology Corp.
Abstract: A selective process for the production of unsymmetric carbamates and ureas is disclosed. In the process, a primary formamide is reacted with a dialkyl amine or an alcohol in the presence of a Group VIII transition metal catalyst. The unsymmetric carbamates and ureas are useful precursors to isocyanates.
Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
October 21, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch
Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
October 14, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch
Abstract: A method of lowering plasma cholesterol level in a patient with hypercholesterolemia, by administration of a compound of formula (1) ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group;Z is a thio, oxy or methylene group;A is a C.sub.1 -C.sub.4 alkylene group; andR.sub.5 is a C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.n --(Ar)wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or napthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C.sub.1 -C.sub.6 alkyl.
Type:
Grant
Filed:
January 2, 1996
Date of Patent:
October 14, 1997
Assignee:
Hoechst Marion Roussel, Inc.
Inventors:
Simon J. T. Mao, Mark T. Yates, Roger A. Parker
Abstract: A method is provided to enhance the ability of a neurologically active compound to penetrate the blood nerve barrier (BNB) or blood brain barrier (BBB), by administration of a conjugate comprising the neurologically active compound linked to a carrier molecule that has been shown to have a substantial permeability coefficient across the BNB and BBB.
Abstract: A pharmaceutical product for the relief of the symptoms of angina pectoris and the like comprises an ester of an organic nitrate and a salicylate or derivative thereof having anti-platelet activity.
Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
September 9, 1997
Assignee:
Carus Corporation
Inventors:
Peter G. Carroll, Stephen T. Isaacs, George D. Cimino
Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
Type:
Grant
Filed:
April 17, 1996
Date of Patent:
September 2, 1997
Inventors:
Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch
Abstract: This invention relates to an application of an anticonvulsant selected from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of said compounds in the preparation of drugs for the treatment of Parkinson's disease and parkinsonian syndromes.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
August 19, 1997
Assignee:
Rhone-Poulenc Rorer S.A.
Inventors:
Alain Boireau, Fran.cedilla.oise Bordier, Adam Doble, Pierre Dubedat, Erik Louvel, Mireille Meunier, Jean-Marie Miquet, Jean-Marie Stutzmann
Abstract: A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA.
Type:
Grant
Filed:
November 30, 1995
Date of Patent:
July 29, 1997
Inventors:
James Henry, Gurpreet Ahluwalia, Douglas Shander
Abstract: A solid composition for peroral therapy of cognition impairment is formulated to stabilize the acid labile drug, CI-979 HCl, by layering a mixture of thereof with a binder on mini-sugar spheres, and finally covering the structure with a protective coating.
Type:
Grant
Filed:
March 7, 1995
Date of Patent:
July 22, 1997
Assignee:
Warner-Lambert Company
Inventors:
Nouman Muhammad, Gary D'Alonzo, Shirley Yang, Jay Weiss
Abstract: A process for the preparation of 2-chloro-4,5-difluorobenzoic acid and 2,4,5-trifluorobenzoic acid as well as synthetic intermediates useful in and prepared according thereto, comprising reacting a nitrobenzene having the formula ##STR1## wherein X is chloro or fluoro, with an appropriate carbanion to form a compound having the formula ##STR2## wherein one of Y and Z is chloro and the other is nitro, and R is a radical selected from the group consisting of --CCl.sub.3, --CH.sub.2 NO.sub.2, --CH(NO.sub.2)R.sup.1, --CH(CO.sub.2 R.sup.1).sub.2, --CH(C(O)R.sup.2).sub.2, --CH(CN)CO.sub.2 R.sup.1, --CH(CO.sub.2 R.sup.1)COR.sup.2 and --COR.sup.2 where R.sup.1 is alkyl or arylalkyl and R.sup.2 is alkyl, aryl or arylalkyl and, where appearing more than once in such a radical, R.sup.1 and R.sup.2 may be the same or different at each occurrence.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
June 10, 1997
Assignee:
Abbott Laboratories
Inventors:
Xiu C. Wang, Panos Kalaritis, Michelle L. Chang
Abstract: Water-soluble aryl imidate activated polyalkylene oxides having improved hydrolytic stability and conjugates of the aryl imidate activated polyalkylene oxides with biologically active nucleophiles are disclosed. Methods of preparing the activated polyalkylene oxides and conjugates thereof are also disclosed.
Abstract: A percutaneous absorptive anesthetic is provided, wherein said anesthetic is formed by mixing a base agent of said anesthetic with one or two type of mixtures which has/have been selected from the groups, for example made of glycyrrhizin, glycyrrhetic acid, glycyrrhetic acid derivatives glycyrrhetic acid 3.beta.-monohemisuccinate, glycyrrhetic acid 3.beta.-monohemisuccinate, 18.beta.-olean-12-ene-3.beta., 30-dihemiphthalate, 18.beta.-olean-9, (11)12-diene-3.beta., 30-diol-dihemiphthalate, olean-11,13(18)-diene-3.beta., 30-diol-dihemiphthalate or their pharmaceutically allowable salt.